The cannabis plant has a lot of medicinal benefits and researchers are continually conducting studies to prove its efficacy in treating some illnesses. It has recently been found that cannabis may have the potential to treat multiple sclerosis.
MMJ International Holdings, the company championing the study of using cannabis to treat multiple sclerosis. According to MMJ, its research into marijuana as a cure for multiple sclerosis is currently before the U.S. Food and Drug Administration (FDA). US health authorities have also placed the study on a ‘Fast Track designation’ as it is about to enter the clinical testing phase.
“Fast Track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. Fast Track addresses a broad range of serious condition,” the FDA describing what Fast Track means.
MMJ International Holdings or MMJ-001 is leading the study of using cannabis to treat muscle stiffness or spasticity that is usually associated with progressive multiple sclerosis in patients. Multiple sclerosis is not the only illness that MMJ-001 is looking to address with cannabis-based drugs. The company is also studying how cannabis can treat Huntington’s associated chorea. Huntington’s disease is defined as a hereditary progressive neurodegenerative disorder. One of the significant symptoms of this disorder is involuntary movements that include akathisia (restlessness), chorea and dystonia (muscle spasms in the head, trunk, and arms). Reports also show that MMJ-001 has requested for the approval of the FDA to conduct tests of their cannabis-based medicine on patients who have Huntington.
MMJ-001 is looking to use a liquid drug made from very potent components of the cannabis plant. This company has isolated some of the most active chemical compounds in cannabis which include Cannabidiol (CBD) and Tetrahydrocannabinol (THC). CBD and THC are two of the most popular compounds in marijuana and have been extensively researched. CBD is usually sold as oils and tinctures, it does not have any psychoactive effects but can make people calm. THC, on the other hand, can get people relaxed but has psychoactive effects. THC is what gets people high when they use marijuana.
MMJ-001 says in a press release that there have been positive data from their studies into treat primary progressive multiple sclerosis (PPMS)with cannabis.
“The positive data from this dosing study is important in that it will provide us with the necessary evidence on patient tolerance to different doses of THC and CBD for the treatment for PPMS,” the CEO is MMJ-001, Duane Boise said. “This information will prove valuable to assist clinicians with prescribing decisions to address individual patient needs should this medicine be FDA approved for use.”
MMJ-001 has become the first company to acquire a license in Canada to produce cannabis-based medicines used in the treatment of multiple sclerosis and Huntington’s disease. The company is now looking to be the first in the US. If they get the approval of the FDA, MMJ-001 will be the first company in the world to produce an entirely natural plant-based drug meant for the treatment of pain and spasticity associated with multiple sclerosis.